Updates on Outcome of AGM
Lincoln Pharmaceuticals Ltd has submitted to BSE a copy of Minutes of 22nd Annual General Meeting ("AGM") held on September 30, 2016.23-10-2016
23-10-2016
Board Meeting on Oct 27, 2016
Lincoln Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 27, 2016, to issue and allotment of equity shares against conversion of warrant issue to Promoter/Promoter Group and Non-Promoter warrant holders.21-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Lincoln Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.14-10-2016
Shareholding for the Period Ended September 30, 2016
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here13-10-2016
Outcome of Board Meeting
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at their meeting held on September 30, 2016, has considered and approved the following:1. Re-appointment of Shri Mahendrabhai G Patel as the Managing Director of the Company with effect from October 01, 2016.2. Re-appointment of Shri Rajnikant G. Patel as the Jt Managing Director of the Company with effect from October 01, 2016....03-10-2016
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Lincoln Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the 22nd Annual General Meeting (AGM) of the Company held on September 30, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report.01-10-2016
Outcome of AGM
Lincoln Pharmaceuticals Ltd has informed BSE that the 22nd Annual General Meeting (AGM) of the Company was held on September 30, 2016.01-10-2016
Lincoln Pharmaceuticals gains on launch of oral spray
The Ondansetron Oral Spray has been launched in the dosage form of 0.2ml equivalent to 2mg and 0.4 ml equivalent to 4mg,23-09-2016
Lincoln Pharmaceuticals Limited has developed New NDDS formulation Ondansetron Oral Spray (Domi Up) "First Time In India"
Lincoln Pharmaceuticals Ltd has informed BSE regarding a Press Release titled "Lincoln Pharmaceuticals Limited has developed New NDDS formulation Ondansetron Oral Spray (Domi Up) "First Time In India"".22-09-2016
Newspaper Advertisement for the Notice of AGM, E voting information & Book Closure
Lincoln Pharmaceuticals Ltd has submitted to BSE a copy of Newspaper Advertisement for the Notice of 22nd Annual General Meeting, E voting information and Book Closure.06-09-2016